pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST
(Plasmid
#174007)
-
PurposeCre dependent co-expression of jGCaMP8s and soma-targeted ChrimsonR under the control of an hSyn promoter. jGCaMP8s and ChrimsonR are separated by cleavable peptide sequence P2A.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 174007 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 | |
AAV9 | 174007-AAV9 | Virus (100 µL at titer ≥ 1×10¹³ vg/mL) and Plasmid. | $405 |
This material is available to academics and nonprofits only.
Backbone
-
Vector backbonepAAV
- Backbone size w/o insert (bp) 4897
- Total vector size (bp) 7504
-
Vector typeAAV
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namejGCaMP8s-P2A-ChrimsonR-ST
-
Insert Size (bp)2607
- Promoter hSyn
-
Tags
/ Fusion Proteins
- soma targeting motif (C terminal on insert)
- 6xHis (N terminal on insert)
Cloning Information
- Cloning method Unknown
- 5′ sequencing primer X2053ST_Asc_R GAGAggcgcgccttagaatctggtggcttcaggga
- 3′ sequencing primer X2046jGCa_NheI_F GAGAgctagcgccaccatgcatcatcaccat (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byAddgene
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Subcloned from:
pAAV-hSyn-DIO-ChrimsonR-mRuby2-ST
(Plasmid #105448)
pGP-AAV-syn-jGCaMP8s-WPRE
(Plasmid #162374)
Please visit https://doi.org/10.1101/2022.09.06.506779 for bioRxiv preprint.
Information for AAV9 (Catalog # 174007-AAV9) ( Back to top )
Purpose
Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST (#174007). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST plasmid DNA.
Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s and soma-targeted ChrimsonR. These AAV preparations are suitable purity for injection into animals.Delivery
- Volume 100 µL
- Titer ≥ 1×10¹³ vg/mL
- Pricing $375 USD for preparation of 100 µL virus + $30 USD for plasmid.
- Storage Store at -80℃. Thaw just before use and keep on ice.
- Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.
Viral Production & Use
- Packaging Plasmids encode adenoviral helper sequences and AAV rep gene, AAV9 cap gene
- Buffer PBS + 0.001% Pluronic F-68
- Serotype AAV9
- Purification Iodixanol gradient ultracentrifugation
Biosafety
Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Viral Quality Control
- Addgene ensures high quality viral vectors by optimizing and standardizing production protocols and performing rigorous quality control (QC) (see a list of our QC assays). The specific QC assays performed varies for each viral lot. To learn which specific QC assays were performed on your lot, please contact us.
- Titer: the exact titer of your sample will be reported on the tube. The titer you see listed on this page is the guaranteed minimum titer. See how titers are measured.
Visit our viral production page for more information.
Addgene Comments
Using FLEX vectors in vivo: LoxP sites in FLEX plasmids are known to recombine during DNA amplification and viral vector production, which may result in a minority of Cre-activated (i.e., "flipped") viral vectors. Addgene has measured this occurs in 0.1-0.8% of viral particles in our typical production protocol. This can lead to a small number of cells exhibiting Cre-independent transgene expression in vivo. To address this, it is necessary to optimize the injection volume and viral titer to find the optimal AAV dosage required for Cre-dependent transgene expression and function in vivo. This may include reducing the viral particle dosage in order to reduce the likelihood of Cre-independent expression.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST was a gift from Mark Histed (Addgene plasmid # 174007 ; http://n2t.net/addgene:174007 ; RRID:Addgene_174007)
For viral preps, please replace (Addgene plasmid # 174007) in the above sentence with: (Addgene viral prep # 174007-AAV9)
-
For your References section:
Bicistronic Expression of a High-Performance Calcium Indicator and Opsin for All-Optical Stimulation and Imaging at Cellular Resolution. LaFosse PK, Zhou Z, Friedman NG, Deng Y, Li AJ, Akitake B, Histed MH. eNeuro. 2023 Mar 29;10(3):ENEURO.0378-22.2023. doi: 10.1523/ENEURO.0378-22.2023. Print 2023 Mar. 10.1523/ENEURO.0378-22.2023 PubMed 36858826